€50.00
Neuroaspis® plp10 is probably the first developed, world patented nutritional supplement in Europe used for pharmaceutical purposes, specifically for the management of people with multiple sclerosis, but also other related neurodegenerative disorders.
20 ml of NEUROASPIS plp10 formulation contains high-quality OMEGA-3 acids (EPA:DHA) (9,000 mg); OMEGA-6 acids (GLA:LA) (9,000 mg); g-tocopherol (vitamin E) (22 mg (33 IU)); beta-carotene (vitamin A) (0.6 mg (1000 IU)).
NEUROASPIS plp10 is a nutritional supplement, which reduces the frequency of disease flares and, more importantly, its progression. It may also be associated with improvement in hearing, vision, movement and muscle numbness. Neuroaspis is a research product which also manages symptoms such as:
Fatigue
Lack of energy
Difficulty in waking up in the morning.
Emotional Changes
Neuroaspis PLP10 should be stored in a cool, dry place away from direct sunlight and heat sources.
NEUROASPIS plp10 is available at selected pharmacies throughout Greece and is distributed by UPPERVIS PHARMACEUTICALS. No prescription is required. In case of additional information, please contact us here. (hyperlink to the contact page)
NEUROASPIS PLP10 is a nutritional supplement specifically designed to overcome known biochemical deficiencies in multiple sclerosis patients associated with the pathophysiology of the disease, including recovery.
It has been tested through a proof-of-concept clinical trial conducted from July 2007 to December 2010 and a 30-month Phase III study completed in 2018 (The MINERAL Study). The formulation has been specifically designed by a team of three Scientists:
Dr. Ioannis Patrikios – Professor of Medical Biochemistry, Lipidologist/ Immunologist Medical School, European University of Cyprus
Dr. Marios Pantzaris – Senior Neurologist, Professor, The Cyprus School of Molecular Medicine
Dr. George Loukaides – Registered Dietician and Clinical Nutritionist
It has been produced according to the innovative method of therapeutic philosophy and approach of the Cypriot scientists of systems medicine, through systems biology. A holistic method applied for the first time towards the treatment of this chronic incurable disease. All ingredients used are of high quality, natural and specially prepared for the requirements of the Neuroaspis plp10 formulation.
Both studies have been published in prestigious, world-renowned medical journals, the British Medical Journal (BMJ), open access, and BMJ Neurology, following independent peer review by world-class scientists with knowledge, long experience and international recognition in multiple sclerosis research and treatment. The product is registered and trademarked in the U.S. as well as worldwide and is available for purchase worldwide.
NEUROASPIS plp10 can be co-administered with all other available therapies. In fact, it has shown great therapeutic effect in reducing the frequency of relapses (flares) of the disease. Finally, it is also potentially able to induce remyelination, neuroprotection and most importantly without side effects. It thus has the potential to influence a holistic treatment of the disease, since it can affect the overall known biological and biochemical network of pathogenic/pathogenetic events and mechanisms that cause the disease, including the biochemical mechanisms responsible for remyelination and neuronal repair (healing). symptoms.
Through collaborations with specialized partners, fully trained professionals, and distinguished scientists in the Health sector, Uppervis Pharmaceuticals aims to establish its presence as a leading pharmaceutical company.